144,691 Shares in Qiagen N.V. $QGEN Bought by Groupe la Francaise

Key Points

• Groupe la Francaise acquired 144,691 shares of Qiagen N.V. for approximately $5.76 million, representing about 0.07% ownership of the company.
• Several institutional investors have increased their holdings in Qiagen, with MetLife Investment Management and Tower Research Capital showing notable increases of 23.6% and 770.6%, respectively, in the last quarter.
• Qiagen's recent quarterly earnings showed a revenue of $533.54 million, marking a 7.7% increase year-over-year, with a consistent earnings per share (EPS) of $0.60 in line with analyst expectations.

Groupe la Francaise bought a new position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 144,691 shares of the company's stock, valued at approximately $5,766,000. Groupe la Francaise owned about 0.07% of Qiagen at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in QGEN. MetLife Investment Management LLC increased its holdings in shares of Qiagen by 23.6% during the 4th quarter. MetLife Investment Management LLC now owns 29,572 shares of the company's stock valued at $1,318,000 after purchasing an additional 5,637 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Qiagen by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Qiagen by 23.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 142,794 shares of the company's stock valued at $6,359,000 after purchasing an additional 27,518 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Qiagen during the 4th quarter valued at approximately $5,645,000. Finally, Earnest Partners LLC increased its holdings in shares of Qiagen by 1.6% during the 4th quarter. Earnest Partners LLC now owns 4,002,489 shares of the company's stock valued at $178,231,000 after purchasing an additional 64,575 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on QGEN shares. Cowen reaffirmed a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen cut Qiagen from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. UBS Group boosted their price objective on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Barclays assumed coverage on Qiagen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Finally, Bank of America boosted their price objective on Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $49.69.

Qiagen Price Performance

NYSE:QGEN opened at $49.7140 on Friday. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The stock has a 50 day moving average of $48.61 and a two-hundred day moving average of $43.89. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The firm has a market cap of $11.05 billion, a P/E ratio of 29.37, a price-to-earnings-growth ratio of 2.61 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same period in the previous year, the business earned $0.55 EPS. Qiagen's quarterly revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Announces Dividend

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. This represents a yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. Qiagen's payout ratio is 14.79%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.